NASDAQ:CTMXCytomX Therapeutics Stock Price, Forecast & News

CytomX Therapeutics' stock was trading at $5.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CTMX stock has increased by 37.1% and is now trading at $8.05. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CytomX Therapeutics.

CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for CytomX Therapeutics.

CytomX Therapeutics Inc (NASDAQ:CTMX) issued its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported $0.26 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.34) by $0.60. The biotechnology company had revenue of $49.59 million for the quarter, compared to analysts' expectations of $26.93 million. CytomX Therapeutics had a negative return on equity of 99.72% and a negative net margin of 97.83%. View CytomX Therapeutics' earnings history.

9 equities research analysts have issued twelve-month price targets for CytomX Therapeutics' shares. Their forecasts range from $7.00 to $16.00. On average, they anticipate CytomX Therapeutics' share price to reach $12.38 in the next twelve months. This suggests a possible upside of 53.7% from the stock's current price. View analysts' price targets for CytomX Therapeutics.

Media stories about CTMX stock have been trending extremely negative recently, according to InfoTrie. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CytomX Therapeutics earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutCytomX Therapeutics.

CytomX Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 1,070,000 shares, a decrease of 14.4% from the April 30th total of 1,250,000 shares. Based on an average daily trading volume, of 536,100 shares, the short-interest ratio is presently 2.0 days. Approximately 2.4% of the shares of the stock are short sold. View CytomX Therapeutics' Current Options Chain.

Some companies that are related to CytomX Therapeutics include Myovant Sciences (MYOV), I-Mab (IMAB), ZEALAND PHARMA/S (ZEAL), Arcus Biosciences (RCUS), Amneal Pharmaceuticals (AMRX), Innoviva (INVA), Portola Pharmaceuticals (PTLA), Intra-Cellular Therapies (ITCI), Tricida (TCDA), Arvinas (ARVN), Karyopharm Therapeutics (KPTI), I-Mab (ARQT), Phathom Pharmaceuticals (PHAT), Supernus Pharmaceuticals (SUPN) and Kiniksa Pharmaceuticals (KNSA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), SCYNEXIS (SCYX), Bausch Health Companies (BHC) and Cidara Therapeutics (CDTX).

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

CytomX Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.65%), Victory Capital Management Inc. (6.04%), Victory Capital Management Inc. (6.04%), State Street Corp (2.15%), First Manhattan Co. (1.73%) and Nuveen Asset Management LLC (1.57%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Lloyd A Rowland and Sean A Mccarthy. View institutional ownership trends for CytomX Therapeutics.

CTMX stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., First Manhattan Co., Squarepoint Ops LLC, Two Sigma Investments LP, Deutsche Bank AG, BlackRock Inc., GSA Capital Partners LLP, and Victory Capital Management Inc.. View insider buying and selling activity for CytomX Therapeutics.

CTMX stock was bought by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Granahan Investment Management Inc. MA, Connor Clark & Lunn Investment Management Ltd., Acadian Asset Management LLC, Russell Investments Group Ltd., Sumitomo Mitsui Trust Holdings Inc., Thrivent Financial for Lutherans, and Geode Capital Management LLC. View insider buying and selling activity for CytomX Therapeutics.

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CTMX stock can currently be purchased for approximately $8.05.

CytomX Therapeutics has a market capitalization of $369.66 million and generates $57.49 million in revenue each year. The biotechnology company earns $-102,240,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. CytomX Therapeutics employs 137 workers across the globe.

The official website for CytomX Therapeutics is www.cytomx.com.

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]